For perhaps the first time, patients suffering from Huntington’s disease have cause for hope. A recent trial conducted by researchers at University College London (UCL) indicates that an experimental drug may significantly suppress a mutated gene related to Huntington’s devastating degenerative effects.
It is estimated that about 30,000 people in the United States and 8,500 people in the UK currently suffer from Huntington's. The disease, which some patients describe as a mix of Alzheimer’s, Parkinson’s and ALS, is responsible for a dizzying array of symptoms. Patients first experience severe mood swings and depression, then face ever-worsening dementia and a gradual loss of motor control that ends in paralysis; the majority die about 10 to 20 years following its onset.